Does sacubitril/valsartan reduce cardiovascular and renal events in patients with heart failure with mildly reduced or preserved ejection fraction?
A pooled analysis of PARAGLIDE-HF and PARAGON-HF supports the use of sacubitril/valsartan to reduce cardiovascular and renal events in patients with HFmrEF/HFpEF, especially those with LVEF below normal.
In pooled analyses of PARAGLIDE-HF and PARAGON-HF, sacubitril/valsartan reduced cardiovascular and renal events among patients with HF with mildly reduced or preserved ejection fraction. These data provide support for use of sacubitril/valsartan in patients with HF with mildly reduced or preserved ejection fraction, particularly among those with an LVEF below normal, regardless of care setting.
Vaduganathan et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: